1. |
Guarascio AJ, Ray SM, Finch CK, et al. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res, 2013, 5: 235-245.
|
2. |
王梦莹, 刘冬静, 黄辉, 等. 慢性阻塞性肺疾病遗传易感性研究进展. 中华流行病学杂志, 2016, 37(12): 1678-1682.
|
3. |
Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med, 2016, 4(5): 390-398.
|
4. |
Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med, 2015, 3(6): 435-442.
|
5. |
Negewo NA, McDonald VM, Baines KJ, et al. Peripheral blood eosinophils: a surrogate marker for airway eosinophilia in stable COPD. Int J Chron Obstruct Pulmon Dis, 2016, 11: 1494-1504.
|
6. |
Zanini A, Cherubino F, Zampogna E, et al. Bronchial hyperresponsiveness, airway inflammation, and reversibility in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis, 2015, 10: 1155-1161.
|
7. |
柳威, 陈荣昌. 慢性阻塞性肺疾病诱导痰细胞分类特点及其与治疗反应性的相关性分析. 中国呼吸与危重监护杂志, 2016, 15(6): 537-541.
|
8. |
Kreindler JL, Watkins ML, Lettis S, et al. Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD. Br Med J Open Respir Res, 2016, 3(1): e000151.
|
9. |
康闪闪, 何晟, 朱恬华, 等. 慢性阻塞性肺疾病急性加重期治疗前后诱导痰细胞分类、血 ECP 变化的临床分析. 中国临床医生, 2014, 42(2): 24-26.
|
10. |
曾强林, 王晓明, 李珊娜, 等. 慢性阻塞性肺疾病急性加重患者血嗜酸粒细胞增高的发生情况及临床特征. 中华医学杂志, 2017, 97(40): 3166-3170.
|
11. |
Zysman M, Deslee G, Caillaud D, et al. Relationship between blood eosinophils, clinical characteristics, and mortality in patients with COPD. Int J Chron Obstruct Pulmon Dis, 2017, 12: 1819-1824.
|
12. |
Duman D, Aksoy E, Agca MC, et al. The utility of inflammatory markers to predict readmissions and mortality in COPD cases with or without eosinophilia. Int J Chron Obstruct Pulmon Dis, 2015, 10: 2469-2478.
|
13. |
DiSantostefano RL, Hinds D, Le HV, et al. Relationship between blood eosinophils and clinical characteristics in a cross-sectional study of a US population-based COPD cohort. Respir Med, 2016, 112: 88-96.
|
14. |
Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J, 2013, 42(3): 636-646.
|
15. |
Eltboli O, Bafadhel M, Hollins F, et al. COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils. BMC Pulm Med, 2014, 14: 112.
|
16. |
Ernst P, Saad N, Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J, 2015, 45(2): 525-537.
|
17. |
Brightling CE. Biomarkers that predict and guide therapy for exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc, 2013, 10(Suppl): S214-S219.
|
18. |
Wedzicha JA, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society Guideline. Eur Respir J, 2017, 49(3): pii: 1600791.
|
19. |
Tworek D, Majewski S, Szewczyk K, et al. The association between airway eosinophilic inflammation and IL-33 in stable non-atopic COPD. Respir Res, 2018, 19(1): 108.
|
20. |
Gunen H, Gulbas G, In E, et al. Venous thromboemboli and exacerbations of COPD. Eur Respir J, 2010, 35(6): 1243-1248.
|
21. |
Bertoletti L, Quenet S, Laporte S, et al. Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry. Respir Res, 2013, 14: 75.
|
22. |
McKeever TM, Hearson G, Housley G, et al. Using venous blood gas analysis in the assessment of COPD exacerbations: a prospective cohort study. Thorax, 2016, 71(3): 210-215.
|
23. |
何浪涛, 何奕涛. 嗜酸性粒细胞对 AECOPD 预后的评估价值. 临床肺科杂志, 2016, 21(6): 1015-1017.
|
24. |
Vedel-Krogh S, Nielsen SF, Lange P, et al. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. Am J Respir Crit Care Med, 2016, 193(9): 965-974.
|
25. |
Kang HS, Rhee CK, Kim SK, et al. Comparison of the clinical characteristics and treatment outcomes of patients requiring hospital admission to treat eosinophilic and neutrophilic exacerbations of COPD. Int J Chron Obstruct Pulmon Dis, 2016, 11: 2467-2473.
|
26. |
Cheng SL, Lin CH. Effectiveness using higher inhaled corticosteroid dosage in patients with COPD by different blood eosinophilic counts. Int J Chron Obstruct Pulmon Dis, 2016, 11: 2341-2348.
|
27. |
Bafadhel M, Greening NJ, Harvey-Dunstan TC, et al. Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD. Chest, 2016, 150(2): 320-328.
|
28. |
Rogliani P, Matera MG, Puxeddu E, et al. Emerging biological therapies for treating chronic obstructive pulmonary disease: a pairwise and network meta-analysis. Pulm Pharmacol Ther, 2018, 50: 28-37.
|